Related Experiment Video
Updated: Aug 17, 2026

Surgical Technique of the 3-Dimensional-printed Personalized Hip Implant for the Treatment of Canine Hip Dysplasia
Published on: April 19, 2024
Tramadol oral solution: new drug. Poorly evaluated and potentially dangerous in children
Insights
Codeine is the standard step-2 opiate analgesic for children. Tramadol, a newer option, has limited trial data, potential harm, and unproven efficacy in pediatric pain management.
Area of Science:
- Pediatric Pharmacology
- Pain Management
- Drug Safety
Background:
- Codeine is the established step-2 opiate analgesic for children aged one year and older.
- Tramadol, a step-2 opiate analgesic, is now approved for children aged three and older in France.
Purpose of the Study:
- To evaluate the evidence supporting the use of tramadol in pediatric pain management.
- To compare the efficacy and safety of tramadol with existing analgesics in children.
Main Methods:
- Review of existing clinical trials and safety data for tramadol in pediatric populations.
- Analysis of comparative studies between tramadol and other analgesics like codeine, paracetamol, and ibuprofen.
Main Results:
- Clinical trials for tramadol in children are limited to short-term postoperative pain.
- Tramadol has not been directly compared to codeine or properly dosed paracetamol in pediatric trials.
- Adverse effects of tramadol in children, such as vomiting, are frequent, and deaths from overdose have been reported, similar to codeine.
Conclusions:
- There is insufficient evidence to support the efficacy of tramadol in children.
- The potential risks associated with tramadol in pediatric patients outweigh the documented benefits.
- Prescribing tramadol for pediatric pain management is not currently justified due to its poorly documented efficacy and safety concerns.
Abstract:
(1) Codeine, either used alone or in combination with paracetamol, is the standard step-2 opiate analgesic for children from the age of one year. (2) An oral solution of tramadol, another step-2 opiate analgesic, was recently approved in France for the treatment of children at least three years of age. (3) The only clinical trials of tramadol in this age group focused on short-term treatment of postoperative pain. Tramadol has not been compared with codeine, ibuprofen, or correctly dosed paracetamol (step-1 analgesic). Tramadol has been compared with diclofenac, a nonsteroidal antiinflammatory drug, in a trial that included patients over 11 years of age (including adults), but the results of this trial are uninformative because patients were not blinded and no separate paediatric subgroup analysis was carried out. (4) The adverse effects of tramadol in children appear to be mild but frequent (especially vomiting). (5) As with codeine, deaths have been reported following accidental overdose with oral tramadol in children. (6) There is no justification for prescribing such a potentially harmful drug with poorly documented efficacy.
Related Concept Videos
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Excretion
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
